Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2681094 | 0.75 | ALDH1A1 (0.35) | ALDH1A1CYP3A4 | |
| SCHEMBL8289230 | 0.71 | ALDH1A1 (0.41) | ALDH1A1CYP3A4CA1CA2CA9 | |
| SCHEMBL14464229 | 0.71 | ALDH1A1 (0.41) | ALDH1A1CYP3A4CA1CA2CA9 | |
| SCHEMBL2680065 | 0.71 | — | — | |
| SCHEMBL891486 | 0.69 | — | — | |
| SCHEMBL2680647 | 0.69 | — | — | |
| SCHEMBL5023481 | 0.67 | — | — | |
| SCHEMBL6610152 | 0.67 | ALDH1A1 (0.50) | ALDH1A1 | |
| SCHEMBL84491 | 0.65 | — | — | |
| SCHEMBL1503396 | 0.58 | ALDH1A1 (0.65) | ALDH1A1CYP3A4CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008081282-A2 | PROCESS FOR THE SYNTHESIS OF N9-(3,5-DICHLORO-4-PYRIDYL)-6- DIFLUOROMETHOXYBENZO(4,5)FURO(3,2-C)PYRIDINE-9-CARBOXAMIDE AND SALTS THEREOF | GLENMARK PHARMACEUTICALS S.A. (US) | 2008-07-10 | — | — | WO | claimed |
| EP-2935239-B1 | PROCESS FOR PREPARING 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDO-4-PYRIDYL)-5-METHOXYPYRIDINE-2-CARBOXAMIDE | SANOFI SA (FR) | 2018-08-29 | — | — | EP | disclosed |
| US-9611250-B2 | Process for preparing 4-(cyclopropylmethoxy)-N-(3,5-dichloro-1-oxido-4-pyridyl)-5-methoxypyridine-2-carboxamide | SANOFI (FR) | 2017-04-04 | — | — | US | disclosed |
| US-9611250-B2 | Process for preparing 4-(cyclopropylmethoxy)-N-(3,5-dichloro-1-oxido-4-pyridyl)-5-methoxypyridine-2-carboxamide | SANOFI (FR) | 2017-04-04 | — | — | US | disclosed |
| US-9533953-B2 | Method of preparation of crystal forms of 4-(cyclopropylmethoxy)-n-(3,5-dichloro-1-oxidopyridyn-4-yl)-5-methoxypyridine-2-carboxamide and crystal forms thereof | SANOFI (FR) | 2017-01-03 | — | — | US | disclosed |
| US-20150322014-A1 | METHOD OF PREPARATION OF CRYSTAL FORMS OF 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDOPYRIDYN-4-YL)-5-METHOXYPYRIDINE-2-CARBOXAMIDE AND CRISTAL FORMS THEREOF | SANOFI (FR) | 2015-11-12 | — | — | US | disclosed |
| US-20150307474-A1 | PROCESS FOR PREPARING 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDO-4-PYRIDYL)-5-METHOXYPYRIDINE-2-CARBOXAMIDE | SANOFI (FR) | 2015-10-29 | — | — | US | disclosed |
| US-20150307474-A1 | PROCESS FOR PREPARING 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDO-4-PYRIDYL)-5-METHOXYPYRIDINE-2-CARBOXAMIDE | SANOFI (FR) | 2015-10-29 | — | — | US | disclosed |
| EP-2935239-A1 | PROCESS FOR PREPARING 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDO-4-PYRIDYL)-5-METHOXYPYRIDINE-2-CARBOXAMIDE | SANOFI (FR) | 2015-10-28 | — | — | EP | disclosed |
| CN-104955820-A | Process for preparing 4-(cyclopropylmethoxy)-n-(3,5-dichloro-1-oxido-4-pyridyl)-5-methoxypyridine-2-carboxamide | SAI NUOFEI | 2015-09-30 | — | — | CN | disclosed |
| US-6303600-B1 | USED IN THERAPY OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY | RHONE-POULENC RORER LIMITED (GB) | 2001-10-16 | — | — | US | disclosed |
| CN-1290266-A | Benzofuran-4-carboxamides and their therapeutical use | DARWIN DISCOVERY LTD (GB) | 2001-04-04 | — | — | CN | disclosed |
| EP-1086106-A1 | FUROPYRIDINE DERIVATIVES AND THEIR THERAPEUTICAL USE | Darwin Discovery Limited (GB) | 2001-03-28 | — | — | EP | disclosed |
| US-6169090-B1 | FOR INHIBITION OF PHOSPHODIESTERASE IV | DARWIN DISCOVERY, LTD. (GB) | 2001-01-02 | — | — | US | disclosed |
| EP-1054884-A1 | BENZOFURAN-4-CARBOXAMIDES AND THEIR THERAPEUTIC USE | Darwin Discovery Limited (GB) | 2000-11-29 | — | — | EP | disclosed |
| US-6066657-A | Benzofuran-4-carboxamides and their therapeutic use | DARWIN DISCOVERY, LTD. (GB) | 2000-05-23 | — | — | US | disclosed |
| WO-1999064423-A1 | FUROPYRIDINE DERIVATIVES AND THEIR THERAPEUTICAL USE | DARWIN DISCOVERY LIMITED (GB) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999040085-A1 | BENZOFURAN-4-CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LIMITED (GB) | 1999-08-12 | — | — | WO | disclosed |
| EP-0934307-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1999-08-11 | — | — | EP | disclosed |
| WO-1997048697-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322014-A1 | METHOD OF PREPARATION OF CRYSTAL FORMS OF 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDOPYRIDYN-4-YL)-5-METHOXYPYRIDINE-2-CARBOXAMIDE AND CRISTAL FORMS THEREOF | COX5B, COX5A, CYCS | ALDH1A1 401/4885CYP3A4 176/4885CA1 298/4885 |
| US-20150307474-A1 | PROCESS FOR PREPARING 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDO-4-PYRIDYL)-5-METHOXYPYRIDINE-2-CARBOXAMIDE | CYP3A4, CYP4B1, CYP3A5 | ALDH1A1 99/4885CYP3A4 1/4885CA1 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.